Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 20;139(21):2440–2450. doi: 10.1161/CIRCULATIONAHA.118.039360

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors.

Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

PMC Copyright notice

Figure 4. — Treatment effect of selexipag on time from randomization to first morbidity or mortality event. A, Treatment effect in subgroups defined by NT-proBNP (N-terminal pro brain natriuretic peptide) level at baseline. B, Treatment effect by time-dependent NT-proBNP category. Low, medium, and high NT-proBNP cutoffs were determined according to baseline NT-proBNP tertiles (low: <271 ng/L; medium: 271–1165 ng/L; high: >1165 ng/L). HR indicates hazard ratio; and N/A, not available.